Guam
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 5.03 (4.31 - 5.86) | 2019 | Modelled | IHME |
| 5.12 (4.38 - 5.93) | 2018 | Modelled | IHME |
| 5.21 (4.35 - 6.12) | 2017 | Modelled | IHME |
| 5.36 (4.57 - 6.28) | 2016 | Modelled | IHME |
| 5.47 (4.63 - 6.38) | 2015 | Modelled | IHME |
| 5.44 (4.62 - 6.30) | 2014 | Modelled | IHME |
| 5.39 (4.58 - 6.22) | 2013 | Modelled | IHME |
| 5.33 (4.53 - 6.14) | 2012 | Modelled | IHME |
| 5.27 (4.46 - 6.06) | 2011 | Modelled | IHME |
| 5.25 (4.41 - 6.06) | 2010 | Modelled | IHME |
| 5.27 (4.46 - 6.05) | 2009 | Modelled | IHME |
| 5.32 (4.51 - 6.13) | 2008 | Modelled | IHME |
| 5.37 (4.57 - 6.19) | 2007 | Modelled | IHME |
| 5.41 (4.58 - 6.25) | 2006 | Modelled | IHME |
| 5.43 (4.59 - 6.33) | 2005 | Modelled | IHME |
| 5.41 (4.58 - 6.26) | 2004 | Modelled | IHME |
| 5.34 (4.49 - 6.24) | 2003 | Modelled | IHME |
| 5.27 (4.38 - 6.20) | 2002 | Modelled | IHME |
| 5.21 (4.25 - 6.17) | 2001 | Modelled | IHME |
| 5.18 (4.21 - 6.15) | 2000 | Modelled | IHME |
| 5.23 (4.28 - 6.17) | 1999 | Modelled | IHME |
| 5.34 (4.44 - 6.35) | 1998 | Modelled | IHME |
| 5.48 (4.60 - 6.56) | 1997 | Modelled | IHME |
| 5.59 (4.75 - 6.74) | 1996 | Modelled | IHME |
| 5.64 (4.78 - 6.84) | 1995 | Modelled | IHME |
| 5.64 (4.79 - 6.82) | 1994 | Modelled | IHME |
| 5.63 (4.77 - 6.80) | 1993 | Modelled | IHME |
| 5.6 (4.71 - 6.78) | 1992 | Modelled | IHME |
| 5.56 (4.62 - 6.76) | 1991 | Modelled | IHME |
| 5.49 (4.46 - 6.68) | 1990 | Modelled | IHME |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.08 (1.41 - 2.84) | 2019 | Modelled | IHME |
| 2.1 (1.43 - 2.89) | 2018 | Modelled | IHME |
| 2.12 (1.44 - 2.97) | 2017 | Modelled | IHME |
| 2.2 (1.50 - 2.97) | 2016 | Modelled | IHME |
| 2.26 (1.54 - 3.02) | 2015 | Modelled | IHME |
| 2.25 (1.53 - 2.98) | 2014 | Modelled | IHME |
| 2.2 (1.50 - 2.91) | 2013 | Modelled | IHME |
| 2.14 (1.47 - 2.83) | 2012 | Modelled | IHME |
| 2.1 (1.44 - 2.78) | 2011 | Modelled | IHME |
| 2.08 (1.43 - 2.78) | 2010 | Modelled | IHME |
| 2.1 (1.44 - 2.79) | 2009 | Modelled | IHME |
| 2.14 (1.45 - 2.85) | 2008 | Modelled | IHME |
| 2.2 (1.46 - 2.94) | 2007 | Modelled | IHME |
| 2.24 (1.47 - 3.01) | 2006 | Modelled | IHME |
| 2.26 (1.45 - 3.04) | 2005 | Modelled | IHME |
| 2.26 (1.47 - 3.01) | 2004 | Modelled | IHME |
| 2.25 (1.47 - 3.01) | 2003 | Modelled | IHME |
| 2.24 (1.45 - 2.99) | 2002 | Modelled | IHME |
| 2.23 (1.44 - 2.99) | 2001 | Modelled | IHME |
| 2.23 (1.42 - 3) | 2000 | Modelled | IHME |
| 2.24 (1.45 - 3) | 1999 | Modelled | IHME |
| 2.28 (1.49 - 3.09) | 1998 | Modelled | IHME |
| 2.33 (1.55 - 3.20) | 1997 | Modelled | IHME |
| 2.37 (1.60 - 3.30) | 1996 | Modelled | IHME |
| 2.39 (1.62 - 3.38) | 1995 | Modelled | IHME |
| 2.39 (1.62 - 3.37) | 1994 | Modelled | IHME |
| 2.4 (1.62 - 3.37) | 1993 | Modelled | IHME |
| 2.4 (1.62 - 3.35) | 1992 | Modelled | IHME |
| 2.39 (1.61 - 3.29) | 1991 | Modelled | IHME |
| 2.38 (1.59 - 3.31) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 11.9 (9.61 - 14.80) | 2019 | Modelled | IHME |
| 11.7 (9.57 - 14.40) | 2018 | Modelled | IHME |
| 11.6 (9.55 - 14.10) | 2017 | Modelled | IHME |
| 11.6 (9.63 - 14) | 2016 | Modelled | IHME |
| 11.4 (9.62 - 13.70) | 2015 | Modelled | IHME |
| 11.2 (9.38 - 13.30) | 2014 | Modelled | IHME |
| 10.9 (9.18 - 12.90) | 2013 | Modelled | IHME |
| 10.5 (8.89 - 12.50) | 2012 | Modelled | IHME |
| 10.2 (8.59 - 12) | 2011 | Modelled | IHME |
| 10.1 (8.54 - 11.90) | 2010 | Modelled | IHME |
| 9.94 (8.43 - 11.60) | 2009 | Modelled | IHME |
| 9.66 (8.17 - 11.40) | 2008 | Modelled | IHME |
| 9.4 (7.90 - 11.10) | 2007 | Modelled | IHME |
| 9.14 (7.61 - 10.70) | 2006 | Modelled | IHME |
| 8.82 (7.37 - 10.40) | 2005 | Modelled | IHME |
| 8.66 (7.25 - 10.20) | 2004 | Modelled | IHME |
| 8.6 (7.18 - 10.10) | 2003 | Modelled | IHME |
| 8.45 (7.04 - 9.98) | 2002 | Modelled | IHME |
| 8.27 (6.92 - 9.77) | 2001 | Modelled | IHME |
| 8.25 (6.87 - 9.77) | 2000 | Modelled | IHME |
| 8.01 (6.72 - 9.51) | 1999 | Modelled | IHME |
| 7.73 (6.45 - 9.17) | 1998 | Modelled | IHME |
| 7.4 (6.17 - 8.77) | 1997 | Modelled | IHME |
| 7.26 (6.01 - 8.69) | 1996 | Modelled | IHME |
| 7.29 (6 - 8.72) | 1995 | Modelled | IHME |
| 7.48 (6.14 - 8.90) | 1994 | Modelled | IHME |
| 7.39 (6.02 - 8.77) | 1993 | Modelled | IHME |
| 7.3 (6 - 8.70) | 1992 | Modelled | IHME |
| 7.22 (5.94 - 8.65) | 1991 | Modelled | IHME |
| 7.12 (5.89 - 8.58) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 20 (16 - 25) | 2019 | Modelled | IHME |
| 20 (16 - 25) | 2018 | Modelled | IHME |
| 20 (16 - 24) | 2017 | Modelled | IHME |
| 19 (16 - 24) | 2016 | Modelled | IHME |
| 19 (16 - 23) | 2015 | Modelled | IHME |
| 19 (16 - 22) | 2014 | Modelled | IHME |
| 18 (15 - 21) | 2013 | Modelled | IHME |
| 17 (15 - 21) | 2012 | Modelled | IHME |
| 17 (14 - 20) | 2011 | Modelled | IHME |
| 17 (14 - 20) | 2010 | Modelled | IHME |
| 16 (14 - 19) | 2009 | Modelled | IHME |
| 16 (13 - 19) | 2008 | Modelled | IHME |
| 15 (13 - 18) | 2007 | Modelled | IHME |
| 15 (12 - 17) | 2006 | Modelled | IHME |
| 14 (12 - 17) | 2005 | Modelled | IHME |
| 14 (12 - 16) | 2004 | Modelled | IHME |
| 14 (12 - 16) | 2003 | Modelled | IHME |
| 14 (11 - 16) | 2002 | Modelled | IHME |
| 13 (11 - 16) | 2001 | Modelled | IHME |
| 13 (11 - 16) | 2000 | Modelled | IHME |
| 13 (11 - 15) | 1999 | Modelled | IHME |
| 12 (10 - 14) | 1998 | Modelled | IHME |
| 11 (10 - 14) | 1997 | Modelled | IHME |
| 11 (9 - 13) | 1996 | Modelled | IHME |
| 11 (9 - 13) | 1995 | Modelled | IHME |
| 11 (9 - 13) | 1994 | Modelled | IHME |
| 11 (9 - 13) | 1993 | Modelled | IHME |
| 10 (9 - 12) | 1992 | Modelled | IHME |
| 10 (8 - 12) | 1991 | Modelled | IHME |
| 10 (8 - 12) | 1990 | Modelled | IHME |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 58 (49 - 67) | 2019 | Modelled | IHME |
| 58 (49 - 67) | 2018 | Modelled | IHME |
| 59 (49 - 67) | 2017 | Modelled | IHME |
| 59 (50 - 68) | 2016 | Modelled | IHME |
| 59 (50 - 68) | 2015 | Modelled | IHME |
| 59 (51 - 68) | 2014 | Modelled | IHME |
| 59 (51 - 67) | 2013 | Modelled | IHME |
| 59 (51 - 67) | 2012 | Modelled | IHME |
| 59 (51 - 68) | 2011 | Modelled | IHME |
| 59 (51 - 68) | 2010 | Modelled | IHME |
| 59 (51 - 67) | 2009 | Modelled | IHME |
| 59 (51 - 67) | 2008 | Modelled | IHME |
| 59 (51 - 67) | 2007 | Modelled | IHME |
| 59 (51 - 68) | 2006 | Modelled | IHME |
| 59 (51 - 68) | 2005 | Modelled | IHME |
| 58 (50 - 67) | 2004 | Modelled | IHME |
| 58 (50 - 66) | 2003 | Modelled | IHME |
| 58 (50 - 67) | 2002 | Modelled | IHME |
| 58 (50 - 67) | 2001 | Modelled | IHME |
| 58 (50 - 67) | 2000 | Modelled | IHME |
| 58 (49 - 66) | 1999 | Modelled | IHME |
| 58 (49 - 66) | 1998 | Modelled | IHME |
| 57 (49 - 66) | 1997 | Modelled | IHME |
| 57 (48 - 65) | 1996 | Modelled | IHME |
| 57 (48 - 66) | 1995 | Modelled | IHME |
| 57 (48 - 66) | 1994 | Modelled | IHME |
| 57 (48 - 66) | 1993 | Modelled | IHME |
| 57 (48 - 66) | 1992 | Modelled | IHME |
| 57 (48 - 66) | 1991 | Modelled | IHME |
| 57 (48 - 67) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.43 (0.34 - 0.52) | 2019 | Modelled | IHME |
| 0.42 (0.34 - 0.52) | 2018 | Modelled | IHME |
| 0.42 (0.34 - 0.52) | 2017 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2016 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2015 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2014 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2013 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2012 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2011 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2010 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2009 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2008 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2007 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2006 | Modelled | IHME |
| 0.42 (0.33 - 0.51) | 2005 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2004 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2003 | Modelled | IHME |
| 0.42 (0.34 - 0.51) | 2002 | Modelled | IHME |
| 0.42 (0.34 - 0.52) | 2001 | Modelled | IHME |
| 0.42 (0.34 - 0.52) | 2000 | Modelled | IHME |
| 0.43 (0.34 - 0.52) | 1999 | Modelled | IHME |
| 0.43 (0.35 - 0.53) | 1998 | Modelled | IHME |
| 0.43 (0.35 - 0.53) | 1997 | Modelled | IHME |
| 0.44 (0.35 - 0.54) | 1996 | Modelled | IHME |
| 0.44 (0.35 - 0.54) | 1995 | Modelled | IHME |
| 0.44 (0.35 - 0.54) | 1994 | Modelled | IHME |
| 0.44 (0.35 - 0.54) | 1993 | Modelled | IHME |
| 0.44 (0.35 - 0.53) | 1992 | Modelled | IHME |
| 0.44 (0.35 - 0.54) | 1991 | Modelled | IHME |
| 0.43 (0.34 - 0.54) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 5.03 (3.75 - 6.59) | 2019 | Modelled | IHME |
| 4.92 (3.71 - 6.47) | 2018 | Modelled | IHME |
| 4.88 (3.71 - 6.29) | 2017 | Modelled | IHME |
| 4.82 (3.64 - 6.25) | 2016 | Modelled | IHME |
| 4.78 (3.64 - 6.17) | 2015 | Modelled | IHME |
| 4.7 (3.61 - 6.02) | 2014 | Modelled | IHME |
| 4.61 (3.56 - 5.89) | 2013 | Modelled | IHME |
| 4.5 (3.46 - 5.71) | 2012 | Modelled | IHME |
| 4.39 (3.37 - 5.61) | 2011 | Modelled | IHME |
| 4.38 (3.35 - 5.61) | 2010 | Modelled | IHME |
| 4.34 (3.30 - 5.55) | 2009 | Modelled | IHME |
| 4.24 (3.22 - 5.40) | 2008 | Modelled | IHME |
| 4.14 (3.17 - 5.25) | 2007 | Modelled | IHME |
| 4.05 (3.11 - 5.14) | 2006 | Modelled | IHME |
| 3.93 (3.01 - 4.98) | 2005 | Modelled | IHME |
| 3.9 (3.03 - 4.95) | 2004 | Modelled | IHME |
| 3.94 (3.05 - 5.01) | 2003 | Modelled | IHME |
| 3.91 (3.01 - 4.98) | 2002 | Modelled | IHME |
| 3.87 (2.97 - 4.94) | 2001 | Modelled | IHME |
| 3.91 (2.99 - 5.02) | 2000 | Modelled | IHME |
| 3.87 (2.95 - 4.96) | 1999 | Modelled | IHME |
| 3.8 (2.90 - 4.86) | 1998 | Modelled | IHME |
| 3.7 (2.83 - 4.74) | 1997 | Modelled | IHME |
| 3.7 (2.85 - 4.79) | 1996 | Modelled | IHME |
| 3.72 (2.85 - 4.83) | 1995 | Modelled | IHME |
| 3.83 (2.90 - 5.01) | 1994 | Modelled | IHME |
| 3.8 (2.89 - 4.92) | 1993 | Modelled | IHME |
| 3.76 (2.86 - 4.84) | 1992 | Modelled | IHME |
| 3.72 (2.86 - 4.79) | 1991 | Modelled | IHME |
| 3.66 (2.80 - 4.74) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 9 (6 - 11) | 2019 | Modelled | IHME |
| 8 (6 - 11) | 2018 | Modelled | IHME |
| 8 (6 - 11) | 2017 | Modelled | IHME |
| 8 (6 - 11) | 2016 | Modelled | IHME |
| 8 (6 - 10) | 2015 | Modelled | IHME |
| 8 (6 - 10) | 2014 | Modelled | IHME |
| 8 (6 - 10) | 2013 | Modelled | IHME |
| 7 (6 - 9) | 2012 | Modelled | IHME |
| 7 (6 - 9) | 2011 | Modelled | IHME |
| 7 (6 - 9) | 2010 | Modelled | IHME |
| 7 (5 - 9) | 2009 | Modelled | IHME |
| 7 (5 - 9) | 2008 | Modelled | IHME |
| 7 (5 - 9) | 2007 | Modelled | IHME |
| 7 (5 - 8) | 2006 | Modelled | IHME |
| 6 (5 - 8) | 2005 | Modelled | IHME |
| 6 (5 - 8) | 2004 | Modelled | IHME |
| 6 (5 - 8) | 2003 | Modelled | IHME |
| 6 (5 - 8) | 2002 | Modelled | IHME |
| 6 (5 - 8) | 2001 | Modelled | IHME |
| 6 (5 - 8) | 2000 | Modelled | IHME |
| 6 (5 - 8) | 1999 | Modelled | IHME |
| 6 (5 - 8) | 1998 | Modelled | IHME |
| 6 (4 - 7) | 1997 | Modelled | IHME |
| 6 (4 - 7) | 1996 | Modelled | IHME |
| 6 (4 - 7) | 1995 | Modelled | IHME |
| 6 (4 - 7) | 1994 | Modelled | IHME |
| 6 (4 - 7) | 1993 | Modelled | IHME |
| 5 (4 - 7) | 1992 | Modelled | IHME |
| 5 (4 - 7) | 1991 | Modelled | IHME |
| 5 (4 - 6) | 1990 | Modelled | IHME |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 16 (11 - 22) | 2019 | Modelled | IHME |
| 16 (11 - 22) | 2018 | Modelled | IHME |
| 16 (11 - 22) | 2017 | Modelled | IHME |
| 16 (11 - 22) | 2016 | Modelled | IHME |
| 16 (11 - 21) | 2015 | Modelled | IHME |
| 16 (11 - 21) | 2014 | Modelled | IHME |
| 16 (11 - 22) | 2013 | Modelled | IHME |
| 16 (11 - 22) | 2012 | Modelled | IHME |
| 16 (11 - 22) | 2011 | Modelled | IHME |
| 16 (11 - 22) | 2010 | Modelled | IHME |
| 16 (11 - 22) | 2009 | Modelled | IHME |
| 16 (11 - 22) | 2008 | Modelled | IHME |
| 16 (11 - 22) | 2007 | Modelled | IHME |
| 16 (11 - 22) | 2006 | Modelled | IHME |
| 16 (11 - 22) | 2005 | Modelled | IHME |
| 17 (11 - 22) | 2004 | Modelled | IHME |
| 17 (12 - 23) | 2003 | Modelled | IHME |
| 17 (11 - 23) | 2002 | Modelled | IHME |
| 17 (11 - 23) | 2001 | Modelled | IHME |
| 17 (11 - 23) | 2000 | Modelled | IHME |
| 17 (12 - 23) | 1999 | Modelled | IHME |
| 17 (12 - 24) | 1998 | Modelled | IHME |
| 18 (12 - 24) | 1997 | Modelled | IHME |
| 18 (12 - 25) | 1996 | Modelled | IHME |
| 18 (12 - 25) | 1995 | Modelled | IHME |
| 18 (12 - 25) | 1994 | Modelled | IHME |
| 18 (12 - 25) | 1993 | Modelled | IHME |
| 18 (12 - 25) | 1992 | Modelled | IHME |
| 18 (12 - 25) | 1991 | Modelled | IHME |
| 18 (12 - 25) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Overview
Prevalence (national)
Modelled
HBV (HBsAg+)
5.03
(%)
2019
(4.31 - 5.86(%))
IHME
HCV (RNA/cAg+)
0.43
(%)
2019
(0.34 - 0.52(%))
IHME
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
20
2019
(16 - 25)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
9
2019
(6 - 11)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
2.08
(%)
2019, latest modelled
(1.41 - 2.84(%))
IHME
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines